# Sutro Biopharma Inc. (STRO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $20.07, market value $333 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Sutro Biopharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 7.3×**. Each dollar of revenue is priced at 7.3×.

## Profitability
- **Operating margin: -319.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -186.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: 144.3%**. A 144.3% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 60.5%**. Return on all capital, debt included, is 60.5%: comfortably above what that capital costs.
- **Return on assets: -103.9%**. Each dollar of assets produces -103.9% of profit.

## Growth
- **Revenue growth (1 yr): 65.2%** (3-yr 14.8%/yr, 5-yr 19.1%/yr). Revenue grew 65.2% over the last year, against 19.1% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 23.5%**. Earnings per share rose 23.5%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.4×**. It would take 0.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 2.01** (quick 2.01). Current assets cover the next year's liabilities 2.01 times.
- **Altman Z-score: -2.31**. A Z-score of -2.31 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Sutro Biopharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Sutro Biopharma Inc.; the consensus is strong_buy, with an average price target of $47.23 (+135% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 96.8%** (YTD 73.5%, 3-mo -23.1%). The shares are up 96.8% over twelve months including dividends.
- **From 52-week high: -54.2%** (180.7% above the low). Trading 54% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 37**. An RSI of 37 is neutral.
- **Beta (1 yr): 1.20** (volatility 90%). Beta of 1.20 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=STRO · Page: https://foliofundamentals.com/stocks/stro

Not investment advice.